Record Nr.	UNINA9910811415603321
Titolo	Advances in cancer research . Volume 125 ABC transporters and cancer // edited by John D. Schuetz, Toshihisa Ishikawa ; contributors Suresh V. Ambudkar [and thirty one others]
Pubbl/distr/stampa	London, England : , : Academic Press, , 2015 ©2015
ISBN	0-12-801361-3
Edizione	[First edition.]
Descrizione fisica	1 online resource (280 p.)
Disciplina	616.9940072
Soggetti	Cancer - Research
ooggetti	Drug resistance in cancer cells
	Cancer - Chemotherapy
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability 2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability.2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to

1.

	brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th; 5.1. P-glycoprotein 5.2. BCRP
Sommario/riassunto	<i>ABC Transporters and Cancer</i> provides invaluable information on the exciting and fast-moving field of cancer research. Here, outstanding and original reviews are presented on a variety of topics. This volume covers ABC transporters and cancer, and is suitable for researchers and students alike. Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students